U.S. market Open. Closes in 5 hours 26 minutes

MDWD | MediWound Ltd. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 14.71 - 15.76
52 Week Range 12.78 - 24.00
Beta 0.51
Implied Volatility 50.91%
IV Rank 41.89%
Day's Volume 124,027
Average Volume 76,820
Shares Outstanding 11,251,800
Market Cap 174,627,936
Sector Healthcare
Industry Biotechnology
IPO Date 2014-03-20
Valuation
Profitability
Growth
Health
P/E Ratio -5.12
Forward P/E Ratio N/A
EPS -3.03
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 100
Country Israel
Website MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
*Chart delayed
Analyzing fundamentals for MDWD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see MDWD Fundamentals page.

Watching at MDWD technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on MDWD Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙